Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonists (tirzepatide) are highly effective for weight loss and cardiovascular risk reduction in adults with obesity.
If lifestyle changes alone haven't worked, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are injectable drugs that mimic hormones to reduce hunger and improve metabolism. They have been shown to produce significant weight loss (14-20%) and improve heart health markers.
StrongSupportsVERY_HIGH confidence
Currently available GLP-1 receptor agonists are liraglutide at a dose of 3.0 mg and semaglutide at a dose of 2.4 mg... Both liraglutide and semaglutide show beneficial effect in the treatment of patients with the risk of cardiovascular events [15,16].
Why this rating
Based on multiple large-scale trials (SCALE, STEP, SURMOUNT) cited in the review.
Source
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Karolina Kuczapska et al. · Journal of Education Health and Sport · 2025
DOI 10.12775/jehs.2025.77.57095
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (gastric bypass, sleeve gastrectomy, duodenal switch) is the most effective intervention for significant weight loss and metabolic benefits in severe obesity.Strong
- Phenotype-guided pharmacotherapy (matching drug mechanism to obesity phenotype) yields significantly greater weight loss than non-phenotype-guided approaches.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →